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ABSTRACT Strongyloidiasis is a parasitic infestation caused by the helminth 
Strongyloides stercoralis. It is essentially gastrointestinal and in general as-
ymptomatic but can sometimes present with skin signs. Immunocompro-
mised patients can develop the disseminated form of the disease due to the 
parasite’s opportunistic behavior, as in cases of coinfection by the human 
T-lymphotropic type 1 virus (HTLV-1). This article presents a case of a patient 
infected with HTLV-I and Strongyloides stercoralis who developed the dissem-
inated form. There were purpuric reticulated periumbilical lesions as well as 
vibices on the patient’s flanks. Histopathologic exam of a skin lesion revealed 
the presence of larvae in the deep reticular dermis. We emphasize the rel-
evance of awareness regarding interaction between HTLV-1 and strongyloi-
diasis, besides identification of the cutaneous manifestations of the disease 
to reach an appropriate therapeutic diagnosis.
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INTRODUCTION 
Strongyloides stercoralis is a parasitic helminth 
worm that can be present in the soil and is capable of 
producing an infestation that may persist for decades. 
Its worldwide prevalence is estimated at around 100 
million infected individuals, reaching up to 50% in 
Latin America and Africa, and may cause death (1).
The initial infestation cycle occurs as the filarial 
larvae penetrate the skin by direct invasion through 
the epidermis, reaching the subcutaneous tissue, 
penetrating into its vessels. They are then drained by 
the venous system until they reach the right heart 
chamber. Subsequently they arrive at the lung capil-
laries, traversing the alveolus from where they follow 
upwards through the bronchial tree and are finally 
swallowed in the gastrointestinal tract (2).
Infected patients may be asymptomatic or pres-
ent diverse clinical manifestations that may resem-
ble a simple peptic disease or present with a severe 
disseminated form of strongyloidiasis, if the larvae 
penetrate the intestinal mucosa, reaching the blood 
stream, causing bacteremia, meningitis, and sepsis, 
especially by Gram-negative bacteria (3).
Disseminated strongyloidiasis is defined by in-
volvement of multiple organs besides the gastroin-
testinal tract and pulmonary system. It is especially 
common in immunosuppressed patients, and that is 
the reason human T-lymphotropic type 1 virus (HTLV-
1) represents a significant risk factor for development 
of hyperinfestation and more severe forms of this dis-
ease (4).
We describe a case of disseminated strongyloidia-
sis with cutaneous involvement in form of purpura 
that developed in an HTLV-1 infected patient.
CASE REPORT
A 53 year-old man working as a mechanic, born 
in the city of Recife, State of Pernambuco, North-
east of Brazil, arrived at the Emergency Room of the 
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University Hospital with a 10-day history of migraine, 
diffuse abdominal pain, cough, fever, and constipa-
tion for 7 days. He had a history of colitis by Strongy-
loides treated in 2012. 
At the time of admission, the patient reported 
having had an episode of hemoptysis the day before, 
with reduced consciousness level, respiratory failure, 
and cutaneous lesions in the abdomen. During physi-
cal examination, he presented tachypnea with 37 in-
cursions per minute, respiratory difficulty, and 60% 
oxygen saturation, receiving a supplementation via 
oxygen mask at a rate of 5 L/min.
Reticulated periumbilical purpuric lesions were 
found at dermatological exam, along with small vibi-
ces in the flanks (Figure 1).
Due to the picture of respiratory failure, the pa-
tient was submitted to orotracheal intubation with a 
ventilatory prosthesis. Additionally, skull, abdomen, 
and pelvis CT scans were carried out, as well as gen-
eral laboratory analyses. The tomography results indi-
cated: normal skull, thorax with diffuse bilateral alve-
olar infiltrate compatible with alveolar hemorrhage, 
and a diffuse thickening of right colon and second 
portion of the duodenum in the abdomen. Labora-
tory analyses revealed mild anemia, absence of leu-
kocytosis and 2% of eosinophils, discrete increase of 
urea, and transaminases. 
The patient was sent to the Intensive Care Unit 
with treatment including daily administration of 
ivermectin @ 200 µg/kg via a nasoenteral probe be-
cause of the strong clinical suspicion of disseminated 
strongyloidiasis. Subsequently, bronchoscopy and 
bronchoalveolar lavage were carried out, as well as 
upper digestive endoscopy with biopsy of the second 
duodenal portion and scalpel biopsy of the cutane-
ous abdominal lesion. During bronchoscopy, a mod-
erate amount of clots were found in the main right 
bronchus. Cytological analysis of the bronchoalveolar 
lavage revealed alveolar macrophages, ciliated cylin-
drical cells, neutrophils, and Strongyloides stercoralis 
larvae (Figure 2). 
Histopathologic exam of the duodenum disclosed 
abundant larvae in the intestinal tissue (Figure 3) and, 
after cutaneous biopsy, the findings included a few 
inflammatory cells, extravasation of red blood cells, 
and presence of larvae throughout the reticular der-
mis (Figure 4), permitting the establishment of a final 
diagnosis of disseminated strongyloidiasis. During 
patient follow-up, HTLV-1 serology was positive for 
Elisa and Western-Blot.
DISCUSSION
Strongyloidiasis can be asymptomatic or present 
extensive symptomatology including a disseminated 
form (5). The symptoms presented by our patient, 
such as headache, abdominal pain, low consciousness 
levels, and dyspnea, belong to the picture of manifes-
tations of the most severe form of the disease.
The most common cutaneous manifestations are 
purpuric, reticulated periumbilical lesions that may 
even affect the proximal region of the lower limbs. 
In our case, in addition to the typical lesions, small 
Figure 1. Reticulated and purpuric lesions on the perium-
bilical region.
Figure 2. Cytological exam: alveolar macrophages, ciliated 
cylindrical cells, neutrophils, and Strongyloides stercoralis 
larvae (Papanicolau, ×400).
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vibices were also found in the flanks, as already previ-
ously mentioned in the literature (6). The initial infes-
tation cycle occurs when the filarial larvae penetrate 
the skin by direct invasion through the epidermis, 
trespassing all dermal levels till the subcutaneous 
tissue. They reach larger vessels that allow their mi-
gration to the lung capillaries. In that location they 
invade the alveoli, climb the bronchial tree and are 
then swallowed into the gastrointestinal tract where 
they reproduce, especially in the small intestine (7,8).
The disseminated form of strongyloidiasis is con-
sidered an event with high mortality, due to the vast 
larvae reproduction in the digestive tube that mi-
grate through the blood flow, thus causing systemic 
dissemination and being able to reach the skin, gas-
trointestinal tract, lungs, and brain. The symptoms 
are variable, including fever, rashes, vomiting, and re-
spiratory discomfort (6). These semiological findings, 
even if unspecific, taken together with the epidemio-
logic history and previous pathologic history lead us 
to carry out an investigation of the cytological analy-
sis of the bronchoalveolar lavage, biopsy of the duo-
denum, and cutaneous histopathology aiming to find 
larvae in the tissues in order to define the diagnosis.
The factors related to a greater probability for oc-
currence of disseminated strongyloidiasis are those 
that cause immunosuppression, especially in cases 
where high doses of corticosteroids have been used 
(even for short periods): presence of AIDS, lympho-
mas and leukemia, and especially infection by HTLV-
1. Several studies (5,8,9) describe a significant associ-
ation between HTLV-1 and hyperinfestation by S. ster-
coralis. There is also a reduced therapeutical response 
in patients infected with the virus concurrently with 
chronic strongyloidiasis. This may be caused by high 
levels of interferon gamma (IFN-γ), which cause de-
viation of the immune response for T-helper 1 (Th1) 
instead of T-helper 2 (Th2), responsible for protection 
against helminths (10).
In the disseminated form, an early diagnosis and 
immediate treatment are of extreme relevance for a 
better prognosis. The most frequent treatment op-
tions include thiabendazole, ivermectin, and alben-
dazole. Ivermectin is a semi-synthetic anti-helminthic 
drug derived from avermectin B1, with a structure 
similar to macrolides but without antibacterial ac-
tion, frequently prescribed for intestinal infestations 
by helminths. Ivermectin is better tolerated when 
compared with thiabendazole, having become the 
medication of choice for treatment of all forms of 
infestation. This medication operates through hyper-
polarization of the neural cells, generating blockage 
of the motor nerve synapse with consequent death 
of the parasite caused by paralysis. The effect does 
not occur in humans, since the substance is unable to 
pass the hematoencephalic barrier. It is employed as 
treatment in several countries, as for instance United 
States and United Kingdom, based on several com-
parative trials that proved its efficacy (11,12).
However, a major limitation is the bioavailability 
of the drug in cases of disseminated disease forms. 
Patients with disseminated forms often present le-
sions in the intestinal lymph vessels as well as in the 
intestinal mucosa caused by the parasite itself, result-
ing in edema of the intestinal wall, reduction of ab-
sorption, and paralysis of the ilium, resulting in poor 
absorption of the anti-helminthic drug. According 
to previously published reports (13,14), veterinary 
preparation ivermectin can be administered by the 
parenteral route.
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Figure 3. Histopathological exam of the duodenum: pres-
ence of larvae in the intestinal tissue (hematoxylin and eo-
sin, ×100).
Figure 4. Histopathological exam of the skin: erythrocytes 
extravasation, few inflammatory cells, and presence of lar-
vae in the reticular dermis around the sweat glands (hema-
toxylin and eosin, ×400).
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CONCLUSION
We described an uncommon case of a patient 
with infestation by Strongyloides stercoralis associ-
ated with HTLV-1, as well as the cutaneous findings 
provoked by the helminths. This parasitic disease is 
potentially lethal and requires a high degree of clini-
cal awareness in order to establish the correct diag-
nosis. In this case, the presence of the dermatologist 
was crucial to reach the correct diagnosis.
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